{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:59:53Z","timestamp":1783515593514,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pathological stage IB-IIIA lung adenocarcinoma  with an epidermal growth factor receptor (EGFR) mutation (Mt)\u00a0has a high recurrence rate even after complete resection. However, there have been few reports on the risk factors for Mt recurrence. This study aimed to analyze the clinicopathological factors related to the relapse-free survival (RFS) of patients with pathological stage IB-IIIA primary lung adenocarcinoma with and without an EGFR mutation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients who underwent curative surgery for Mt (<jats:italic>n<\/jats:italic>\u2009=\u2009208) harboring the EGFR exon 21 L858R point mutation or EGFR exon 19 deletion mutation and EGFR mutation wild-type lung adenocarcinoma (Wt, <jats:italic>n<\/jats:italic>\u2009=\u2009358) between January 2010 and December 2020 were included. Patients who received adjuvant EGFR-tyrosine kinase inhibitors were excluded. The prognostic factors for RFS were analyzed using a multivariable Cox regression analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 5-year RFS rates in the Mt and Wt groups were 43.5 and 52.3%, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.907). Prognostic factors for RFS in the Mt group included smoking history (hazard ratio [HR], 1.49; <jats:italic>p<\/jats:italic>\u2009=\u20090.049), blood vessel invasion (HR, 1.84; <jats:italic>p<\/jats:italic>\u2009=\u20090.023), and lymph node metastasis (HR, 1.96; <jats:italic>p<\/jats:italic>\u2009=\u20090.005). However, adjuvant chemotherapy was not a prognostic factor (HR, 1.02; <jats:italic>p<\/jats:italic>\u2009=\u20090.906). In contrast, positron emission tomography (PET) max standardized uptake value (SUV)\u2009\u2265\u20096.0 (HR, 1.53; <jats:italic>p<\/jats:italic>\u2009=\u20090.042), lymphatic vessel invasion (HR, 1.54; <jats:italic>p<\/jats:italic>\u2009=\u20090.036), lymph node metastasis (HR, 1.79; <jats:italic>p<\/jats:italic>\u2009=\u20090.002), and adjuvant chemotherapy (HR, 0.60; <jats:italic>p<\/jats:italic>\u2009=\u20090.008) were prognostic factors for RFS in the Wt group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Prognostic factors for RFS in stage IB-IIIA primary lung adenocarcinoma differ by epidermal growth factor receptor mutation status. The impact of adjuvant chemotherapy on RFS also differed by EGFR mutation status.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10057-w","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T21:03:03Z","timestamp":1662757383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status"],"prefix":"10.1186","volume":"22","author":[{"given":"Tetsuya","family":"Isaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Yokose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritake","family":"Kikunishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Rino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"issue":"10","key":"10057_CR1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa0904554","volume":"361","author":"R Rosell","year":"2009","unstructured":"Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958\u201367.","journal-title":"N Engl J Med"},{"issue":"42","key":"10057_CR2","doi-asserted-by":"publisher","first-page":"e1784","DOI":"10.1097\/MD.0000000000001784","volume":"94","author":"T Isaka","year":"2015","unstructured":"Isaka T, Yokose T, Ito H, Nagata M, Furumoto H, Nishii T, et al. Correlations between the EGFR mutation status and Clinicopathological features of clinical stage I lung adenocarcinoma. Medicine (Baltimore). 2015;94(42):e1784.","journal-title":"Medicine (Baltimore)"},{"issue":"5578","key":"10057_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","volume":"297","author":"IB Weinstein","year":"2002","unstructured":"Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002;297(5578):63\u20134.","journal-title":"Science."},{"issue":"1","key":"10057_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350.","journal-title":"N Engl J Med"},{"issue":"2","key":"10057_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213\u201322.","journal-title":"Lancet Oncol"},{"issue":"2","key":"10057_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, et al. Gefitinib alone versus Gefitinib plus chemotherapy for non-small-cell lung Cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38(2):115\u201323.","journal-title":"J Clin Oncol"},{"issue":"2","key":"10057_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejcsup.2013.07.023","volume":"11","author":"KM Kerr","year":"2013","unstructured":"Kerr KM, Nicolson MC. Prognostic factors in resected lung carcinomas. EJC Suppl. 2013;11(2):137\u201349.","journal-title":"EJC Suppl"},{"key":"10057_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2020.04.012","volume":"145","author":"T Isaka","year":"2020","unstructured":"Isaka T, Ito H, Nakayama H, Yokose T, Yamada K, Masuda M. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification. Lung Cancer. 2020;145:111\u20138.","journal-title":"Lung Cancer"},{"key":"10057_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.lungcan.2021.11.002","volume":"162","author":"T Isaka","year":"2021","unstructured":"Isaka T, Ito H, Nakayama H, Yokose T, Saito H, Adachi H, et al. Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM classification) primary lung cancer after curative surgery. Lung Cancer. 2021;162:128\u201334.","journal-title":"Lung Cancer"},{"issue":"3","key":"10057_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.21.01729","volume":"40","author":"H Tada","year":"2022","unstructured":"Tada H, Mitsudomi T, Misumi T, Sugio K, Tsuboi M, Okamoto I, et al. Randomized phase III study of Gefitinib versus cisplatin plus Vinorelbine for patients with resected stage II-IIIA non-small-cell lung Cancer with EGFR mutation (IMPACT). J Clin Oncol. 2022;40(3):231\u201341.","journal-title":"J Clin Oncol"},{"issue":"34","key":"10057_CR11","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","volume":"33","author":"K Kelly","year":"2015","unstructured":"Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crin\u00f2 L, et al. Adjuvant Erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung Cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33(34):4007\u201314.","journal-title":"J Clin Oncol"},{"issue":"1","key":"10057_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","volume":"19","author":"WZ Zhong","year":"2018","unstructured":"Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139\u201348.","journal-title":"Lancet Oncol."},{"issue":"7","key":"10057_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1200\/JCO.20.01820","volume":"39","author":"WZ Zhong","year":"2021","unstructured":"Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, et al. Gefitinib versus Vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 2021;39(7):713\u201322.","journal-title":"J Clin Oncol"},{"issue":"18","key":"10057_CR14","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung Cancer. N Engl J Med. 2020;383(18):1711\u201323.","journal-title":"N Engl J Med"},{"issue":"3","key":"10057_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/1758834014521110","volume":"6","author":"C D'Antonio","year":"2014","unstructured":"D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 2014;6(3):101\u201314.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10057_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/ejcts\/ezab442","volume":"61","author":"T Isaka","year":"2022","unstructured":"Isaka T, Ito H, Nakayama H, Yokose T, Saito H, Masuda M. Impact of the initial site of recurrence on prognosis after curative surgery for primary lung cancer. Eur J Cardiothorac Surg. 2022;61(4):778\u201386.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"10057_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung Cancer. J Thorac Oncol. 2016;11(1):39\u201351.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10057_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/14737159.2017.1288568","volume":"17","author":"U Malapelle","year":"2017","unstructured":"Malapelle U, Sirera R, Jantus-Lewintre E, Reclusa P, Calabuig-Fari\u00f1as S, Blasco A, et al. Profile of the Roche cobas\u00ae EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017;17(3):209\u201315.","journal-title":"Expert Rev Mol Diagn"},{"issue":"5","key":"10057_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/jclinpath-2012-201240","volume":"66","author":"F Lopez-Rios","year":"2013","unstructured":"Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, et al. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol. 2013;66(5):381\u20135.","journal-title":"J Clin Pathol"},{"key":"10057_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/01243894-200701000-00006","volume":"2","author":"K Yoshida","year":"2007","unstructured":"Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol. 2007;2:22\u20138.","journal-title":"J Thorac Oncol"},{"key":"10057_CR21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2353\/jmoldx.2006.060030","volume":"8","author":"S Matsukuma","year":"2006","unstructured":"Matsukuma S, Yoshihara M, Kasai F, et al. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loophybrid mobility shift assay. J Mol Diagn. 2006;8:504\u201312.","journal-title":"J Mol Diagn"},{"key":"10057_CR22","volume-title":"WHO classification of Tumours of the lung, pleura, Thymus and heart","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of Tumours of the lung, pleura, Thymus and heart. Lyon: International Agency for Research on Cancer; 2015."},{"issue":"1","key":"10057_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JTO.0b013e3182769aa8","volume":"8","author":"A Yoshizawa","year":"2013","unstructured":"Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC\/ATS\/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013;8(1):52\u201361.","journal-title":"J Thorac Oncol"},{"key":"10057_CR24","doi-asserted-by":"crossref","unstructured":"Isaka T, Nakayama H, Ito H, Yokose T, Yamada K, Masuda M. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery. BMC Cancer. 2018;18(1):959.","DOI":"10.1186\/s12885-018-4849-9"},{"issue":"6","key":"10057_CR25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.21037\/tlcr.2019.12.02","volume":"8","author":"J Ni","year":"2019","unstructured":"Ni J, Guo T, Li Y, Yang X, Li Y, Zou L, et al. Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers. Transl Lung Cancer Res. 2019;8(6):967\u201378.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"10057_CR26","doi-asserted-by":"publisher","first-page":"e2131892","DOI":"10.1001\/jamanetworkopen.2021.31892","volume":"4","author":"SPL Saw","year":"2021","unstructured":"Saw SPL, Zhou S, Chen J, Lai G, Ang MK, Chua K, et al. Association of Clinicopathologic and Molecular Tumor Features with Recurrence in resected early-stage epidermal growth factor receptor-positive non-small cell lung Cancer. JAMA Netw Open. 2021;4(11):e2131892.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10057_CR27","first-page":"1420","volume":"6","author":"C Park","year":"2014","unstructured":"Park C, Lee IJ, Jang SH, Lee JW. Factors affecting tumor recurrence after curative surgery for NSCLC: impacts of lymphovascular invasion on early tumor recurrence. J Thorac Dis. 2014;6(10):1420\u20138.","journal-title":"J Thorac Dis"},{"key":"10057_CR28","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/JTO.0b013e3182519a42","volume":"7","author":"KA Higgins","year":"2012","unstructured":"Higgins KA, Chino JP, Ready N, et al. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. J Thorac Oncol. 2012;7:1141\u20137.","journal-title":"J Thorac Oncol"},{"key":"10057_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s11748-013-0340-3","volume":"62","author":"S Shiono","year":"2014","unstructured":"Shiono S, Kanauchi N, Yanagawa N, et al. Stage II-IV lung cancer cases with lymphovascular invasion relapse within 2 years after surgery. Gen Thorac Cardiovasc Surg. 2014;62:112\u20138.","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"1","key":"10057_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/JTO.0b013e3181f8a1f1","volume":"6","author":"M Harada","year":"2011","unstructured":"Harada M, Hato T, Horio H. Intratumoral lymphatic vessel involvement is an invasive indicator of completely resected pathologic stage I non-small cell lung cancer. J Thorac Oncol. 2011;6(1):48\u201354.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10057_CR31","doi-asserted-by":"publisher","first-page":"e28844","DOI":"10.1371\/journal.pone.0028844","volume":"6","author":"J Wang","year":"2011","unstructured":"Wang J, Chen J, Chen X, Wang B, Li K, Bi J. Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2011;6(12):e28844.","journal-title":"PLoS One"},{"issue":"5","key":"10057_CR32","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.jtcvs.2018.06.034","volume":"156","author":"S Wang","year":"2018","unstructured":"Wang S, Xu J, Wang R, Qian F, Yang W, Qiao R, et al. Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion. J Thorac Cardiovasc Surg. 2018;156(5):2006\u20132015.e2.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"10057_CR33","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.lungcan.2012.04.002","volume":"77","author":"T Kato","year":"2012","unstructured":"Kato T, Ishikawa K, Aragaki M, Sato M, Okamoto K, Ishibashi T, et al. Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma. Lung Cancer. 2012;77(2):394\u2013400.","journal-title":"Lung Cancer"},{"issue":"6","key":"10057_CR34","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.jtcvs.2013.11.050","volume":"147","author":"T Mimae","year":"2014","unstructured":"Mimae T, Tsutani Y, Miyata Y, Yoshiya T, Ibuki Y, Kushitani K, et al. Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma. J Thorac Cardiovasc Surg. 2014;147(6):1820\u20136.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8","key":"10057_CR35","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.neo.2015.08.002","volume":"17","author":"P Minder","year":"2015","unstructured":"Minder P, Zajac E, Quigley JP, Deryugina EI. EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation. Neoplasia. 2015;17(8):634\u201349.","journal-title":"Neoplasia."},{"issue":"8","key":"10057_CR36","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1002\/jcp.22548","volume":"226","author":"A De Luca","year":"2011","unstructured":"De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D\u2019Alessio A, et al. Role of the EGFR ligand\/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol. 2011;226(8):2131\u20138.","journal-title":"J Cell Physiol"},{"issue":"5","key":"10057_CR37","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/cancers14051356","volume":"14","author":"TY Lin","year":"2022","unstructured":"Lin TY, Yang CH, Chou HC, Cheng CM, Liu YW, Wang JY, et al. EGFR mutation-harboring lung Cancer cells produce CLEC11A with endothelial trophic and tumor-promoting activities. Cancers (Basel). 2022;14(5):1356.","journal-title":"Cancers (Basel)"},{"issue":"58","key":"10057_CR38","doi-asserted-by":"publisher","first-page":"98384","DOI":"10.18632\/oncotarget.21842","volume":"8","author":"CH Tseng","year":"2017","unstructured":"Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017;8(58):98384\u201393.","journal-title":"Oncotarget."},{"issue":"3","key":"10057_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1634\/theoncologist.2014-0285","volume":"20","author":"Y Hasegawa","year":"2015","unstructured":"Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, et al. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. Oncologist. 2015;20(3):307\u201315.","journal-title":"Oncologist."},{"issue":"6","key":"10057_CR40","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","volume":"150","author":"M Imielinski","year":"2012","unstructured":"Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107\u201320.","journal-title":"Cell."},{"issue":"6","key":"10057_CR41","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","volume":"150","author":"R Govindan","year":"2012","unstructured":"Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150(6):1121\u201334.","journal-title":"Cell."},{"issue":"2","key":"10057_CR42","first-page":"100","volume":"8","author":"M Su\u00e1rez-Pi\u00f1era","year":"2018","unstructured":"Su\u00e1rez-Pi\u00f1era M, Belda-Sanchis J, Taus A, S\u00e1nchez-Font A, Mestre-Fusco A, Jim\u00e9nez M, et al. FDG PET-CT SUVmax and IASLC\/ATS\/ERS histologic classification: a new profile of lung adenocarcinoma with prognostic value. Am J Nucl Med Mol Imaging. 2018;8(2):100\u20139.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"22","key":"10057_CR43","first-page":"00097","volume":"S0022-5223","author":"Y Tsutani","year":"2022","unstructured":"Tsutani Y, Ito M, Shimada Y, Ito H, Ikeda N, Nakayama H, et al. The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. J Thorac Cardiovasc Surg. 2022;S0022-5223(22):00097\u20136.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10057_CR44","doi-asserted-by":"crossref","unstructured":"Isaka T, Ito H, Nakayama H, Yokose T, Katayama K, Yamada K, et al. Efficacy of platinum-based adjuvant chemotherapy on prognosis of pathological stage II\/III lung adenocarcinoma based on EGFR mutation status: a propensity score matching analysis. Mol Diagn Ther. 2019;23(5):657\u201365.","DOI":"10.1007\/s40291-019-00419-9"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10057-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T22:06:28Z","timestamp":1662761188000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10057-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10057"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10057-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"assertion":[{"value":"29 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study conformed to the Declaration of Helsinki on Human Research Ethics standards and was approved by the ethics committee of the Kanagawa Cancer Center (2021 Eki-153). Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"966"}}